---
filename: arrhythmias-you-cant-miss.md
id: arrhythmias-you-cant-miss
title: Arrhythmias You Can’t Miss
slug: arrhythmias-you-cant-miss
tags: [cardiology, inpatient, night-float]
level: resident
estimated_time_min: 25
version: 2026-02-20
source: IM_NightFloat_Engine
---

# Arrhythmias You Can’t Miss

## Panic Card
- Check responsiveness, pulse, and ABCs; place on monitor, defibrillator at bedside; target **MAP ≥65 mmHg**, **SpO₂ ≥94%**.
- Unstable tachyarrhythmia (hypotension, shock, chest pain, altered mental status): immediate **synchronized cardioversion 100–200 J biphasic**; escalate if ineffective.
- Pulseless VT/VF: **defibrillate 200 J biphasic**, high‑quality CPR, epinephrine **1 mg IV q3–5 min**, consider amiodarone **300 mg IV push** after second shock.
- Torsades de pointes: **magnesium sulfate 2 g IV over 10–15 min**, repeat once if needed; correct **K⁺ to 4.0–4.5 mmol/L**; consider overdrive pacing if recurrent.
- Symptomatic bradycardia: **atropine 1 mg IV q3–5 min (max 3 mg)**; if ineffective, **transcutaneous pacing** and start **dopamine 5–20 µg/kg/min** or **epinephrine 2–10 µg/min** infusion.
- **Confirm Before Proceed:** If AF + pre‑excitation (irregular wide‑complex tachycardia), avoid AV nodal blockers (adenosine, diltiazem, beta‑blockers, digoxin); use **procainamide** or synchronized cardioversion.

## Brief Overview
- Night‑float success hinges on rapidly distinguishing stable vs unstable rhythms; instability mandates electricity first (synchronized cardioversion for organized tachyarrhythmias, defibrillation for pulseless/irregular polymorphic VT). Keep pads on, oxygen, IV access, and airway readiness.
- **Guideline Must‑Know:** AHA ACLS recommends immediate synchronized cardioversion for tachyarrhythmias with hypotension, shock, ischemic chest pain, acute heart failure, or altered mental status; start at **100–200 J biphasic** and escalate as needed.
- **Guideline Must‑Know:** For symptomatic bradycardia, give **atropine 1 mg IV**, repeat q3–5 min to **3 mg max**; if ineffective, pace and consider **dopamine 5–20 µg/kg/min** or **epinephrine 2–10 µg/min** infusions.
- **Guideline Must‑Know:** Torsades de pointes (polymorphic VT with prolonged QT) requires **magnesium sulfate 2 g IV over 10–15 min**, correction of **K⁺ 4.0–4.5 mmol/L, Mg²⁺ ≥0.8 mmol/L**, removal of QT‑prolonging drugs, and possible overdrive pacing.
- **Guideline Must‑Know:** In AF with pre‑excitation (WPW pattern), avoid AV nodal blockers; use **procainamide 10 mg/kg IV over 20–30 min** if stable or synchronized cardioversion if unstable.
- **Guideline Must‑Know:** Stable monomorphic wide‑complex tachycardia of uncertain origin should be treated as VT; preferred IV options include **amiodarone 150 mg over 10 min**, repeat as needed, then infusion **1 mg/min**.
- **Guideline Must‑Know:** High‑grade AV block (Mobitz II or complete heart block) with symptoms warrants **temporary pacing** and evaluation for reversible causes (ischemia, drugs, hyperkalemia); consult cardiology early for permanent pacing needs.
- When the rhythm is unclear, prioritize patient status: oxygenation, perfusion, and mental status. Get a 12‑lead ECG quickly but do not delay life‑saving cardioversion/defibrillation for diagnostics.
- Common precipitants at night: ischemia, hypoxemia, sepsis, **K⁺/Mg²⁺ abnormalities**, drug effects (e.g., sotalol, amiodarone interactions, digoxin), and missed beta‑blocker doses. Replace electrolytes early and aggressively within safety limits.
- Misleading patterns: AF with aberrancy vs VT—treat uncertain wide‑complex tachycardia as VT. Irregular wide‑complex tachycardia suggests AF with pre‑excitation; electricity or procainamide, not AV nodal blockers.
- What must happen now: stabilize, attach defib pads, verify hemodynamics, obtain ECG, correct electrolytes, prepare sedation for cardioversion, and call ICU if escalating support is needed. What can wait: long‑term anticoagulation strategy, EP study planning, and upstream risk modification.
- **Guideline Must‑Know:** For pulseless VT/VF, defibrillation plus high‑quality CPR, **epinephrine 1 mg IV q3–5 min**, and **amiodarone 300 mg IV push** (then **150 mg**) improves defibrillation success; resume compressions immediately after shocks.
- **Guideline Must‑Know:** Rate control in hemodynamically stable AF with RVR typically uses **diltiazem** or **metoprolol**; however, in decompensated HFrEF, prefer **amiodarone** or **digoxin** for rate control; electricity for instability.
- Pitfalls: Giving amiodarone for torsades (can worsen QT), using adenosine in irregular wide‑complex tachycardia with pre‑excitation, or delaying pacing in complete heart block. Recognize drug accumulation in CKD and avoid multiple AV nodal blockers together.
- Call ICU/Consult: refractory VT/VF, recurrent torsades, complete heart block not responding to atropine, unstable AF/flutter requiring repeated cardioversion, or need for temporary transvenous pacing or antiarrhythmic infusions with vasopressors.

## Top ICU/Consult Triggers
- Persistent or recurrent VT/VF, torsades, or need for **>1** cardioversion/defibrillation with ongoing instability.
- High‑grade AV block with hypotension, syncope, or bradycardia **<40/min** requiring pacing or vasoactive infusions.
- Escalating oxygen/pressor requirements, ischemia with dynamic ST changes, or rising troponin with malignant arrhythmia.
- Wide‑complex tachycardia requiring antiarrhythmic infusion and continuous titration or need for temporary transvenous pacing.

## Orders to Place Now
- Order: 12‑Lead ECG — {STAT acquisition; repeat after intervention}
- Order: Continuous cardiac monitoring — {telemetry with external defibrillation/pacing pads applied}
- Order: Electrolyte repletion — {potassium goal 4.0–4.5 mmol/L; magnesium goal ≥0.8 mmol/L; protocolized IV/PO replacement}
- Order: Antiarrhythmic infusion — {amiodarone 150 mg IV over 10 min → 1 mg/min for 6 h → 0.5 mg/min; adjust for hypotension}
- Order: Synchronized cardioversion — {energy {100–200 J biphasic}, sedation {etomidate 0.15–0.3 mg/kg or ketamine 0.5–1 mg/kg}, oxygen and suction ready}

## ABIM‑Style Question 1

### Stem
A 62‑year‑old man with palpitations and dizziness becomes hypotensive (BP 78/48 mmHg). Monitor shows an irregular wide‑complex tachycardia at 180/min; ECG reveals delta waves when briefly slower. He is diaphoretic and confused.

### Options
A. Adenosine rapid IV push  
B. Diltiazem IV bolus  
C. Synchronized cardioversion  
D. Metoprolol IV bolus  
E. Digoxin IV load

### Correct answer
C

### Rationale
Unstable AF with pre‑excitation requires immediate **synchronized cardioversion**. AV nodal blockers (adenosine, diltiazem, beta‑blockers, digoxin) can accelerate conduction down the accessory pathway and precipitate VF. When stable, **procainamide** is preferred for AF with WPW.

## Second ABIM‑Style Case (Pitfall Variant)

### Stem
A 55‑year‑old woman on sotalol for PVCs presents with syncope. ECG shows polymorphic VT with prolonged QTc 530 ms. She is awake with BP 92/56 mmHg and ongoing runs of torsades.

### Options
A. Amiodarone IV bolus  
B. Magnesium sulfate 2 g IV over 10–15 min  
C. Diltiazem IV bolus  
D. Lidocaine IV bolus  
E. Immediate thrombolysis

### Correct answer
B

### Rationale
Torsades due to QT prolongation is treated with **magnesium sulfate 2 g IV**, electrolyte optimization (**K⁺ 4.0–4.5 mmol/L; Mg²⁺ ≥0.8 mmol/L**), and stopping QT‑prolonging drugs; overdrive pacing if recurrent. The pitfall is giving **amiodarone**, which can further prolong QT.

What changed the decision here?

## Check‑Yourself Micro‑Questions
- Q: First step for unstable organized tachyarrhythmia?  
  A: Immediate synchronized cardioversion with **100–200 J biphasic**, do not delay for ECG interpretation.
- Q: Atropine dose for symptomatic bradycardia?  
  A: **1 mg IV q3–5 min** to a **maximum of 3 mg**, then pacing/infusion if ineffective.
- Q: Initial magnesium dose for torsades de pointes?  
  A: **2 g IV over 10–15 min**, may repeat once; consider infusion and overdrive pacing if recurrent.
- Q: Electrolyte targets on telemetry to reduce ectopy?  
  A: **K⁺ 4.0–4.5 mmol/L** and **Mg²⁺ ≥0.8 mmol/L**, unless contraindicated by renal function.

## Guidelines & Key References
- AHA Adult ACLS Tachycardia/Bradycardia Algorithms, 2020 with focused updates 2023–2024 — https://cpr.heart.org
- 2023 ACC/AHA/ACCP/HRS Guideline for the Management of Atrial Fibrillation — https://www.ahajournals.org/doi/10.1161/CIR.0000000000001193
- 2018 ACC/AHA/HRS Guideline on the Evaluation and Management of Patients With Bradycardia and Cardiac Conduction Delay — https://www.ahajournals.org/doi/10.1161/CIR.0000000000000628
- 2017 AHA/ACC/HRS Guideline for Management of Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death — https://www.ahajournals.org/doi/10.1161/CIR.0000000000000549
- AHA Scientific Statement on Drug‑Induced Arrhythmias (QT prolongation), 2020 — https://www.ahajournals.org/doi/10.1161/CIR.0000000000000905

## CDI: What to Document Clearly Tonight
- Arrhythmia diagnosis + acuity: e.g., “Unstable monomorphic VT” or “Symptomatic complete heart block” with hemodynamic effects (hypotension, shock, altered mental status).
- Etiology/cause: ischemia, electrolyte disturbance (e.g., hypokalemia, drug‑induced QT prolongation), structural heart disease, or conduction disease.
- Severity/organ dysfunction: need for cardioversion/defibrillation, vasoactive support, pacing, respiratory failure, lactate elevation.
- Objective evidence: ECG rhythm/intervals (QRS/QTc), vitals, troponin, electrolytes (K⁺, Mg²⁺), imaging if ischemia suspected.
- Treatment/monitoring: cardioversion/defibrillation energy, antiarrhythmic doses, pacing parameters, electrolyte targets, continuous telemetry, and consults placed.
